Merck & Co. Inc.
NYS : MRK
Pharmaceuticals
Whitehouse Station NJ
Pharmaceuticals
Whitehouse Station NJ
Current Rank Rank | 28 |
Prior Rank | 27 |
Executive 1 | Kenneth Frazier, Chairman; President; Chief Executive Officer |
Executive 2 | Peter N. Kellogg, Chief Financial Officer |
IW Best50 | N/A |
2012 Revenue (US$ Millions) | $47,267 |
2011 Revenue (US$ Millions) | $48,047 |
Revenue Growth (%) | -1.62% |
Net Income (US$ Millions) | $6,168 |
Common Shares Outstanding (Millions) | $3,027 |
Earnings Per Share (US$) | $2.00 |
Total Equity (US$ Millions) | $53,020 |
Profit Growth (%) | -1.66 |
Profit Margin (%) | 13.05% |
Return On Equity (%) | 11.31% |
Long Term Debt (US$ Millions) | $16,254 |
Debt To Equity Ratio (%) | 0.31% |
Market Capitalization (US$ Millions) | $123,910 |
Total Assets (US$ Millions) | $106,132 |
Return on Assets (%) | 5.87 |
Current Assets (US$ Millions) | $34,857 |
Inventories (US$ Millions) | $6,535 |
Current Liabilities (US$ Millions) | $18,348 |
Cost of Goods Sold (US$ Millions) | $16,446 |
Asset Turnover | 0.45 |
Inventory Turnover | 2.57 |